# US 2024/0189402 A1 · Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189402 A1
- Document ID: US20240189402A1
- Status: Published application
- Kind: A1
- Application number: 18/585,914
- Filed: 2024-02-23
- Published: 2024-06-13
- Earliest claimed: 2016-12-08
- Inventors: Gary E. Borodic
- Web page: https://patentgrep.com/patent/US20240189402A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 27/02: Ophthalmic agents
- C07K 16/22: against growth factors {; against growth regulators}
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin. The disclosed formulations may be applied to an intraocular or extraocular region of a patient. If applied to an extra ocular region of a patient, the botulinum-based pharmaceutical formulation may then be transported to the intra-ocular region of the patient, allowing the active ingredient(s) to penetrate into the choroid, neuro-retina, and/or retinal pigment epithelium without direct injection into the eye, eliminating risk of retinal detachment, retinal break, retinal hemorrhage, and blindness. Additionally, relative timing of botulinum application and specific staging of wet, exudative macular degeneration relative to the paraorbital applications are disclosed. Further, a mammalian model is proposed to determine the fraction of botulinum most effective at altering VEGF production and associated with suppression of chorio-retinal leakage from macular pathologies.

## Claims

### Claim 1

A method of treating and/or retarding progression of diabetic retinopathy, the method comprising:
identifying a patient with diabetic retinopathy with vascular leakage and/or neovascularization;
administering an intra ocular injection of an anti-VEGF; and
administering an injection of a botulinum toxin into a para orbital region of the patient at a conventional dose,
wherein injecting the botulinum toxin reduces the need for additional anti-VEGF injections, reducing risk of retinal detachment, endophthalmitis, cataract, glaucoma and retinal break, and preserving and improving vision.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-VEGF is selected from the group comprising of aflibercept; ranibizumab; bevacizumab; abicipar; broluzimab, and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anti-VEGF is administered at a dose range from 5 to 200 units.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-VEGF is administered at a dose range from 200 to 600 units.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anti-VEGF is administered at an adjusted range according to a formulation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the botulinum toxin is a pure type A neurotoxin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the botulinum toxin is a complexed type A neurotoxin.

### Claim 8 (depends on 1)

The method of claim 1, further comprising one or more repeated injections of the botulinum toxin into the patient.

### Claim 9 (depends on 1)

The method of claim 1, further comprising monitoring the patient by visual acuity, ocular coherence tomography (OCT) and/or fluoresceine angiography.

### Claim 10

A method of treating and/or retarding progression of macular degeneration, the method comprising:
identifying a patient with macular degeneration;
administering an intra ocular injection of an anti-VEGF with vaso-occlusive properties; and
administering an injection of a botulinum toxin into a para orbital region of the patient,
wherein the botulinum toxin mitigates anti-VEGF induced reduction of choriocapillaris flow, reducing damage to retinal pigment epithelium and photoreceptors.

### Claim 11 (depends on 10)

The method of claim 10, wherein the macular degeneration is exudative macular degeneration.

### Claim 12 (depends on 10)

The method of claim 10, wherein the macular degeneration is dry macular degeneration.

### Claim 13 (depends on 10)

The method of claim 10, wherein the anti-VEGF is selected from the group comprising of aflibercept; ranibizumab; bevacizumab; abicipar; broluzimab, and combinations thereof.

### Claim 14 (depends on 10)

The method of claim 10, wherein the botulinum toxin is a botulinum neurotoxin type A.

### Claim 15 (depends on 10)

The method of claim 10, further comprising one or more repeated injections of the botulinum toxin into the patient.

### Claim 16 (depends on 10)

The method of claim 10, further comprising post-analysis of the injection of the type A botulinum toxin by ocular coherence tomography angiography (OCT-A).
